Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
24/09/2026 20:21
BRIEF-FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component Sept 24 (Reuters) - FDA:
FDA APPROVES BELZUTIFAN IN COMBINATION WITH LENVATINIB FOR ADVANCED RENAL CELL CARCINOMA WITH A CLEAR CELL COMPONENT
FDA: RECOMMENDED DOSAGE IS 20 MG OF LENVATINIB IN COMBINATION WITH 120 MG OF BELZUTIFAN ONCE DAILY UNTIL DISEASE PROGRESSION OR UNACCEPTABLE TOXICITY
Further company coverage: MRK.N
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China